Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$$$$ After a long and arduous wait, it looks like the SAFER Banking Act, the renamed version of the bipartisan law that would allow banks to work with cannabis businesses without penalties, is finally showing some traction after languishing in Congress. Today, the Senate Committee on Banking, Housing and Urban Affairs held a “markup” on the legislation and as expected, the bill passed decisively.
Although members of the House did overwhelmingly vote for the SAFE Banking Act, the bill’s earlier version, several times before, today’s vote marks the first time that Senate members have voted in favor of the measure.
Now it’s off to the Senate and the House for more debate, amendment and votes before hopefully proceeding to President Biden’s desk. If all goes well, the banking ban that has been the scourge of the legal cannabis industry since its inception will be lifted.
$MMNFF
I told people buyer beware when the shares were at $.15!
Buyer's Beware!Warning! This security is eligible for Unsolicited Quotes Only
This stock is not eligible for proprietary broker-dealer quotations. All quotes in this stock reflect unsolicited customer orders. Unsolicited-Only stocks have a higher risk of wider spreads, increased volatility, and price dislocations. Investors may have difficulty selling this stock. An initial review by a broker-dealer under SEC Rule15c2-11 is required for brokers to publish competing quotes and provide continuous market making.
T??I
Is bud cars still exist
0.0001 shameful
TREN, TOLD YA!
Thanks captain obvious
ECGI is just another reverse merger pump and dump. they are also affiliated with NUGS scheme and ECGI is run by the same Chinese associates that destroyed SGMD. You are welcome.
Ask 0.0002
Ask 0.0002
ECGI Has A Low Float You Are Welcome To Join In On It Under 15 Million .
Sugarmade Is A Scam Billions Of Shares Dumped Nothing Here But A Revers Split ! ATM Shut Down !
Anyone invest in budcars,
www.otcmarkets.com
Warning! This security is eligible for Unsolicited Quotes Only
This stock is not eligible for proprietary broker-dealer quotations. All quotes in this stock reflect unsolicited customer orders. Unsolicited-Only stocks have a higher risk of wider spreads, increased volatility, and price dislocations. Investors may have difficulty selling this stock. An initial review by a broker-dealer under SEC Rule15c2-11 is required for brokers to publish competing quotes and provide continuous market making.
Anyone buy at 0.0001 and then to sell when
Double today
Interesting buyers
0.0001 go up or reverse split
Volume = Dilution not liquidity when the share price drops.
Liquidity is not dilution if the share price rises.
Liquidity and dilution are one and the same, the word chosen depends on the price.
Since all these schemes drop in price, its all dilution because liquid means you can sell shares easily but at a lower price. buy high sell low what a strategy.
Volume
They still going to NASDAQ? lol
0.0001 lol
What are the chances of a reverse split
Sugarmade Inc. holders, jimmy chan (all lowercase), bought hubs (Sugarmade.com), land, and vehicles with Shareholders' money, and now he's pocketing off your dime. Call FINRA, OTCMarkets, and The Sec. of State of California and explain to them about all the assets he bought with Shareholders Money. Now, he's the only one benefiting after all the misleading statements he put out there.
Smart to invest in bud cars
Anyone get 0.0001 recently, have not been here for a while
Doubled today so far
EDDYF (EDDYD) just did a 1/8. I may have to short that ticker at $.16 My daughters agrees when she says "mommy why do you always say people love to lose money" I say because they do.
0.0001 WHAT
The POT delivery cars "Bud Cars" did not exist, they were photoshopped VW's. Google BUD cars and you only see 4 images of cars that did not exist except on the desktop of a graphics designer.
The pot delivery cars a while back, wonder what is going on now
Right on, Suissac. Mr. Chan's latest "venture" from this past February has produced zero pump since the announcement. No CEO in his right mind would offer $70 million for two distressed hot desert area hotels, and be convinced that they are good opportunities for "PUB-CO" action. Have not heard a word since the announcement. I'm sure you agree. Mr. Chan is a fraud, and he is bilking any shareholder who doesn't know what's going on. If it was a good deal, he would buy it for his LMK Corporation.
I have been following Sugarmade since 2018, and not one thing jimmy chan (all lowercase), has PR'd has come to pass. This guy should be shut down, and when I see him do any type of Pump and Dump from here on out, I'm reporting it immediately.
OK. If people know ALL the stocks they are buying into that none of the money goes to the company you think they would just HOLD off on buying. These stocks are a lotto play not an investment strategy. They play just to gamble and know full well they will never win. If they thought for one instance they would win on any given ticker they would invest $10,000 not just $100.
I already know that. Hence, my post.
I lost complete faith a couple of years ago in this stock. Changing business strategies, acquisitions and complicated partnerships with revenue and growth estimates that never materialize, If I have missed something and this has better prospects than i think please let me know ! GLTA
3cents, it's really not a tangled web, it's just 3 or 4 people running the scheme with Jimmy being the least paid. Hes just the patsy CEO who makes very little to issues shares to the debt investors. I posted this over on another ticker page, Maybe this will sink in the reality of it all.
There is no limit to the shares that can be issued to the float.
The company puts fake debt on the books.
Debt investors agree to pay $20,000 in debt for 100,000,000 restricted shares
As the shares are diluted to the float, the debt investors pay less and less for each 100,000,000. As the shares drop the float increases and the company CEO keeps the debt payments and does not use the money to help the company.
The debt investors file 3(a)10 to have those shares made free trading
The shares the debt investors now own that YOU are buying, are NOT owned by the company. You are giving you money to a private individual not associated with the company!!!!!!
The SHARES YOU ALL BUY, none of your money goes to the CEO or the company. You are buying shares that have no longer a link to the company.
That is why all these TICKERS drop to red red red.
As long as retail suckers keep buying these stocks thinking it’s going to the company to make their scheme plans work, they will keep having shares to sell.
As long as there is debt with no limit to shares, the float will rise and the stock will fall.
The company says they are going to expand but the money you all invested does not go to the company.
Can’t you all see that when these stinky pinky’s raise $50,000,000 or more you never see the money on their financials because the company did NOT get the money.
Am I the only one who sees this?
ALL YOU INVESTORS who are buying shares, the money is NOT GOING to the company! AND the CEO's are all in on the scheme.
Get it through your thick heads. GOOD LORD!
What a tangled web. Mr. Chan is in cahoots with all these thieves.
Sugar Rush, Inc Is This You ? Page #38 https://www.otcmarkets.com/otcapi/company/financial-report/366025/content
1 Entry into a Material Definitive Agreement.
The information set forth in Item 5.02 of this Current Report on Form 8-K is incorporated herein by reference.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 13, 2023, Salona Global Medical Device Corporation (the "Company") exercised its right to terminate the employment of Luke Faulstick as the Company's President and Chief Executive Officer. Mr. Faulstick will continue as a member of the Company's Board of Directors.
On June 13, 2023, upon terminating Mr. Faulstick, the Company appointed Michael Seckler, 58, to the position of Interim Chief Executive Officer, effective immediately. From October 2022 through May 2023, Mr. Seckler served as Chief Operating Officer and from March 2020 through September 2022 served as Senior Vice President Operations of FerGene, a gene therapy company affiliated with Ferring International Center, SA , a Swiss multinational biopharmaceutical company ("Ferring"). From June 2017 through February 2020, Mr. Seckler was Vice President Global Marketing and Communications at Ferring.
In connection with Mr. Seckler's appointment as Interim Chief Executive Officer, he will be paid an annual salary of US$100,000 and variable compensation based on incentives of up to US$200,000 annually. Additionally, he has ?been granted options under the Company's Stock Option Plan to acquire an aggregate of 250,000 Common Shares of the Company, over a three-year period, vesting 1/3 per year for three years, at an ?exercise price of CAD$0.25 per share. The options and underlying Common Shares are ?subject to a four-month and one day hold period pursuant to the rules of the TSX Venture Exchange. In addition, Mr. Seckler will be eligible to participate in the benefit programs generally available to executive officers of the Company.
There are no arrangements or understandings between Mr. Seckler and any other persons pursuant to which he was selected as Interim Chief Executive Officer. There are also no family relationships between Mr. Seckler and any director or executive officer of the Company and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
On June 2, 2023, the Company terminated the employment of Joseph Martinez, but Mr. Martinez continues to be available to the Company on an hourly basis as a consultant pursuant to the terms of a consulting agreement, and on June 13, 2023 he ceased to hold the titles of Senior Vice President, Legal & Compliance, General Counsel and Secretary of the Company.
What I would have in mind is not all 5000 penny stocks but rather a rule specifically for biotech stocks, and perhaps energy innovation stocks that trade under $5.00. There are 84 million Americans who live with pain everyday due to disease, injury or old age. The best possible medical care requires new ideas and new drugs, procedures or devices.
My proposition is that biotech, since it serves our most important and urgent needs would be protected from legal financial corruption.If you bought a share you can sell that share anytime if you are small fry retail. Institutions, HF, and wealthy traders would have a holding period. They can not sell short until the PPS is over $5.00.
Companies would still be able to raise money by selling shares. The toxic convertible debt problem could be avoided it seems to me. Dilution is surely a problem for investors, but the secret collusive schemes to go naked short and then massively dilute could be controlled. When the share price is significantly higher because of a lack of deceptive collusive share selling schemes then the shares that get sold are more effective in raising the needed capital for the company. These are just my ideas. Tell me why I am wrong about this.
The bad actors who make so much money through the legal corruption might have a compassion for curing diseases or saving our planet from a climate disaster. They could still make their ill begotten money on the myriad companies that do things that don’t really matter much.
Thanks
Besao, quick reply.
1) How about you come back to me when they DO get FDA approval for the cancer cure and not FDA approval on the method of its delivery (Oral or by injection) I can get DA approval for a new way to dispense water from a bottle its that easy. Show me the FDA on the cancer cure or treatment then well talk about that.
2) The ONLY way debt shares are issued that is the ONLY way shares are diluted and drop in price is due to DEBT 3(a)10 rule that allows someone who pays debt to get what ever amount of shares they want so they can dilute them for less then the bid and add to the float killing the price.
Get rig of 3(1)10 so you cant get shares free traded when paying debt and the OTC will lose 5,000 or more tickers the next day. But the OTC charges $10,000 annually for each ticker so they would lose in revenue $50,000,000 annually and the 5,000 pump and dumps would lose about $100 BILLION annually combined in sucker stock buys from 100's of millions of sucker retailers.
With that much money on the line, Regulations will never change.
Thanks MallenNV for that court case. There is so much corruption from all sides except for the gullible long retail investor who places trust almost blindly.
If NWBO gets FDA approval to treat glioblastoma perhaps that would overcome the massive debt. The shorts are thinking that those are long odds and that they would be able to cover before that ever happens.
Do you see any reforms that could make the penny stock market more transparent and fair for the gullible and vulnerable retail investor?
Is short selling a necessary feature for efficient price discovery? Perhaps short selling should not be allowed for a security that is below a certain market cap. Stocks that are held long would be allowed to be sold, but no short selling or naked short selling. What harm would be done by doing this to protect small companies from abusive practices?
Toxic convertible debt could also be regulated to eliminate abusive practices similar to the usury laws that limit outrageous interest rates from being imposed.
Thanks
NWBO is a development stage company (Means they have and do nothing) they operate out of “YET AGAIN” an office suite.
They have 1 billion shares in the float and 1,700,000,000 authorized (For now). That means they have 700,000,000 to use on debt conversions.
5 ticker changes.
They have massive debt and no cash! With no cash they have no choice but to debt dilute, take the cash and blame others to divert shareholders from a class action. Although some have and are suing the company. Seems like your typical debt diluted scheme.
As per the SEC;
SEC Files Settled Action Against Biotechnology Company Related to Unremediated Material Weaknesses Spanning Twelve Years
ADMINISTRATIVE PROCEEDING
File No. 3-19582
October 10, 2019 - The Securities and Exchange Commission today filed a settled action against Northwest Biotherapeutics (NWBO) for failing to maintain internal control over financial reporting (ICFR) for twelve consecutive annual reporting periods. In each of its annual Form 10-K filings with the Commission over more than a decade, NWBO disclosed material weaknesses, many of which recurred year after year, with insufficient effort at remediation.
ALSO! $41 million in stock options to debt dump to investors.
A Northwest Biotherapeutics Inc. Investor sued members of its board in Delaware, claiming they gave themselves nearly $41 million in stock options in an “unprecedented and indefensible” effort to offset the dilutive effects of a financing transaction that caused them “absolutely no economic harm.”
The lawsuit, made public Wednesday, alleges a “gross abuse” of fiduciary power by the directors who engineered the “true-up” deal after issuing equity on terms that equally diluted every stockholder while increasing the company’s overall value. The board members and general counsel, who also participated in the true-up, had no right “to own a specific percentage ...
Andrews & Springer LLC announces that it has filed a class action lawsuit on behalf of Northwest Biotherapeutics, Inc. ("NWBO") and minority shareholders in the Delaware Court of Chancery - Case No. 11179. NWBO is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments without toxicities of the kind associated with chemotherapies.
The complaint alleges that NWBO's Board of Directors along with its CEO and Chairperson Linda Powers ("Powers") and entities under her control -- Toucan Capital Fund III, L.P., Toucan Partners LLC and Cognate Bioservices, Inc. ("Cognate") -- breached their fiduciary duties by causing the Company to convert some of Cognate's outstanding invoices and future invoices (for prior services provided to the Company) into NWBO equity at an unfair price at the expense of the Company and minority shareholders.
Paying off debt to convert to debt shares to sell cheap, that was a company action not the MM's.
Any of the news about this being the market makers fault may be true but the company set them up to debt dilute. I thing the company is just blaming others for actions they did to get sympathy from investors to prevent another class action while the company unloads more shares to get out before they ticker is deleted.
Its ALL ABOUT self enrichment nothing else. https://nwbio.com/Stipulation%20of%20Settlement.pdf
The problems that we discuss are being addressed directly in a court case filed by NorthWest Biotherapeutics NWBO. The troublesome issues are most pronounced in the small cap biotech arena. The following is a comment placed on the NWBO board where the harms are being addressed and the plaintiffs are attempting to have the corruption become specifically delineated.
“We all agree that spoofing of any company developing a life-saving treatment and the associated naked shorting which it facilitates is reprehensible in the extreme.
We all know that this results in a depressed share price (and hence the value of the company).
We all know that a Nobel Prize winning economists affirms that this is not a transient phenomenon but has long term effects on the share price.
In the submission by Cohen Millstein against Market Makers, Citadel and other hedge funds, the claim is made that:
The company believes that the market makers directly impacted the price of Northwest Biotherapeutics’ shares in the market .... causing Northwest Biotherapeutics to suffer significant losses as it sold millions of shares at artificially depressed prices and was slowed in bringing its encouraging drugs to market.
I would like to ask 2 questions:
1] Is there any actual evidence that spoofing or any form of shorting has ever resulted in a delay in obtaining regulatory licencing for a therapeutic, and specifically for DCVax-L?
2] If there is such evidence, can the delay to the licencing of DCVax-L be quantified?
If there is a quantifiable delay, I would hope that Ms. Posner of Cohen Millstein would provide Judge Gabriel Gorenstein with a fairly accurate assessment of how many patients in the USA died from GBM having been denied the possibility of curative treatment with DCVax-L because of the delay in its licencing consequent upon the illegal spoofing.
One would certainly hope that with such information, the case would go to trial so that the defendants could not buy their way out of being exposed for what they are and that this would allow Judge Gorenstein to make the punishment fit the crime.”
Thanks
Fair and efficient price discovery cannot happen with all of this MM collusion that we have discussed and analyzed. The individual retail investors need to let the regulatory agencies and congress know about their concerns.
Do you think there is anybody who is educated and articulate that is currently reaching out to convey the salient information to make changes that protect the integrity of investing with regard to penny stocks and those stocks trading under $5.00?
Ultimately, like you have said before, it is Congress that must make amendments to the laws.
Is there a limited wealth retail investor association?
Thanks.
Followers
|
495
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
53051
|
Created
|
08/11/06
|
Type
|
Free
|
Moderators |
Email: info@sugarmade.com Phone: (626) 346-9512
OTC MARKETS - QUICK LINKS
QUOTE
NEWS
DISCLOSURE
SECURITY DETAILS
SEC (EDGAR) - (OTCQB:SQMD) FILINGS
SEC FILINGS
On January 23, 2019 Sugarmade, Inc. (the “Company”) announced the signing of a Letter of Intent (the “LOI”) to acquire a retail location of Washington State-based Hydro4Less. The LOI outlines the general terms of a possible acquisition transaction. Pending the signing of a definitive agreement, Sugarmade will issue Five Million Dollars ($5,000,000) of its common shares at a price pegged at Ten Cents ($0.10) to the owners of Hydro4Less in exchange for the single retail operation, not including inventories on hand.
Additionally, via the pending transaction, Sugarmade will gain an option, at an acquisition price to be determined later, to purchase two additional Hydro4Less retail operations, which are currently producing in excess of Twenty Million Dollars ($20,000,000) annually. The single location acquisition that is the subject of the LOI, is expected to produce approximately Five Million Dollars ($5,000,000) for calendar year 2019 and is currently operating at a profit with positive operating cash flow. The Company believes the single location the acquisition would be accretive to earning for Sugarmade. Should all three acquisitions close, Sugarmade will increase its annual revenues by approximately Twenty Five Million Dollars ($25,000,000) million per year.
Hydro4Less is significant supplier to the growing hydroponic cultivation sector. Neither the Company nor Hydro4Less conduct any business involving the sale of any cannabis product or relating to any products containing cannabis.